Investment Rating - The report maintains an "Outperform" rating for China Medical System Holdings (867 HK) with a target price of HK$18.63, reflecting a potential upside from the current price of HK$12.96 [2][8]. Core Insights - The company achieved a revenue of CNY8.2 billion in FY25, representing a 10% year-on-year increase, with pharmaceutical sales revenue reaching CNY9.4 billion. The gross profit margin was 71.5%, down 1.1 percentage points year-on-year. Net profit was CNY1.4 billion, a decrease of 11% year-on-year, primarily due to one-off tax impacts [3][14]. - Exclusive and innovative products drove steady sales growth, with revenue from these products increasing by 44% year-on-year. Key products contributing to this growth include Velphoro, Metoject, Ilumya, Valtoco, and Mucopolysaccharide Polysulfate Cream [4][15]. - The approval and launch of Ruxolitinib cream for vitiligo in January 2026 is expected to generate significant sales, with management projecting revenue of at least CNY500 million in 2026 and peak sales of no less than CNY6 billion [5][16]. Financial Performance - Revenue projections for FY26 and FY27 have been revised to CNY9.6 billion and CNY11.4 billion, respectively, reflecting the expected contribution from innovative product launches. Attributable net profit forecasts for FY26 and FY27 have been adjusted to CNY1.7 billion and CNY1.9 billion, respectively, due to increased R&D spending [8][18]. - The breakdown of revenue by segment for FY25 shows: Cardiovascular and cerebrovascular segment at CNY4.2 billion (+2.3% YoY), Gastroenterology/autoimmune segment at CNY3.0 billion (+3.3% YoY), Skin health segment at CNY1.1 billion (+73.2% YoY), Ophthalmology segment at CNY0.7 billion (+12.9% YoY), and Other products at CNY0.46 billion (+10.3% YoY) [20].

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 65.80 and a fair value of HKD 91.95 [5]. Core Insights - The company, Lin Qingxuan, is a leading high-end domestic skincare brand in China, known for its innovative "oil-based skincare" concept. It ranks as the 13th largest high-end skincare brand in China with a market share of 1.4% in 2024 [11][17]. - The company has achieved significant revenue growth, with a CAGR of 32% from 2022 to 2024, and reported a revenue of RMB 1.052 billion in the first half of 2025, representing a year-on-year increase of 98.3% [11][27]. - The company's flagship product, Camellia Oil Essence, has sold over 45 million bottles and has been the top-selling facial oil product in China for 11 consecutive years [11][17]. - The company has successfully integrated an OMO (Online-Merge-Offline) channel model, with 554 stores nationwide, leading the high-end skincare segment in store count [11][17]. Financial Performance - The company's main revenue is projected to grow from RMB 805 million in 2023 to RMB 4.732 billion by 2027, with growth rates of 16.5%, 50.3%, 99.4%, 45.2%, and 35.1% respectively [3]. - EBITDA is expected to increase from RMB 181 million in 2023 to RMB 975 million in 2027, reflecting strong operational efficiency [3]. - Net profit attributable to shareholders is forecasted to rise from RMB 85 million in 2023 to RMB 798 million in 2027, with growth rates of 121.1%, 92.4%, 59.6%, and 39.1% [3]. Market Position and Strategy - Lin Qingxuan has established a strong brand identity through its focus on high-quality ingredients like Camellia and small molecule peptides, with nearly 70% of its revenue coming from high-end products such as essence oils, creams, and serums [11][17]. - The company has leveraged social media platforms like Douyin (TikTok) for rapid growth, achieving a 328% increase in revenue from this channel in the first half of 2025 [11][17]. - The company plans to use proceeds from its IPO to enhance brand value, expand its sales network, and improve production and supply chain capabilities [47][48]. Industry Overview - The Chinese cosmetics market is projected to grow to RMB 688.6 billion by 2024, with skincare products accounting for 67% of this market [51][52]. - The facial oil market is expected to reach RMB 5.3 billion by 2024, with a CAGR of 42.8% from 2019 to 2024, driven by the increasing demand for anti-aging and skin-tightening products [52][59]. - Online sales of skincare products are anticipated to grow significantly, with an expected online penetration rate of 55.3% by 2024 [59].

Group 1 - Investment Rating: Buy for both CATL (3750) and Bilibili (BILI) [3][20] - Target Price: CATL's target price is set at 725 HKD, representing an 11% upside from the current price [11]. Bilibili's target price is 38.00 USD, indicating a potential increase of 50.8% [20] - Market Capitalization: CATL has a market cap of 3 trillion HKD, while Bilibili's market cap is 10.54 billion USD [6][13] Group 2 - CATL's 2025 Performance: The company achieved a revenue of 423.7 billion RMB, a 17% year-on-year increase, and a net profit of 72.2 billion RMB, up 42.3% [7]. The gross margin improved to 26.3% [7] - Battery Market Share: CATL's market share in the global battery market reached 39.2%, maintaining its position as the world's largest battery manufacturer for nine consecutive years [8] - Bilibili's Revenue Growth: Bilibili reported a total revenue of 30.35 billion RMB in 2025, a 13.1% increase year-on-year, and achieved its first annual GAAP profit [16][20] Group 3 - CATL's R&D Investment: The company invested 22.15 billion RMB in R&D, a 19.02% increase, focusing on new battery technologies and solutions [10] - Bilibili's Advertising Revenue: The advertising revenue for Q4 reached 3.04 billion RMB, a 27% year-on-year increase, benefiting from improved efficiency and expanded scenarios [17] - User Growth for Bilibili: The average daily active users (DAU) reached 112 million, an 8% increase year-on-year, indicating strong user engagement [19]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [9]. Core Insights - The company achieved a revenue of 94.58 billion yuan in 2025, reflecting a year-on-year growth of 1.2%. However, the net profit attributable to shareholders decreased by 26.3% to 2.99 billion yuan, primarily due to a decline in gross margin from 24.6% to 21.4% [4][6]. - The company continues to expand its operations, with the number of stores increasing by 18.5% year-on-year to 61,139, and the number of agents rising by 4.6% to 523,000 [6]. - The report highlights the company's commitment to shareholder returns, with a share buyback amounting to 9.21 billion USD, representing approximately 4.1% of the total shares outstanding as of the end of 2024 [6]. Financial Performance Summary - Revenue Forecast: - 2024: 93.46 billion yuan - 2025: 94.58 billion yuan - 2026: 102.62 billion yuan - 2027: 111.55 billion yuan - 2028: 121.70 billion yuan - Year-on-year growth rates: 20% (2024), 1% (2025), 9% (2026-2028) [3][7] - Net Profit Forecast: - 2024: 4.07 billion yuan - 2025: 2.99 billion yuan - 2026: 4.12 billion yuan - 2027: 4.82 billion yuan - 2028: 6.00 billion yuan - Year-on-year growth rates: -31% (2024), -26% (2025), 38% (2026), 17% (2027), 25% (2028) [3][7] - Earnings Per Share (EPS): - 2024: 1.15 yuan - 2025: 0.85 yuan - 2026: 1.17 yuan - 2027: 1.37 yuan - 2028: 1.70 yuan [3][7] - Price-to-Earnings (P/E) Ratio: - 2024: 34.1 - 2025: 46.3 - 2026: 33.7 - 2027: 28.8 - 2028: 23.1 [3][7] Market Environment and Business Segments - The existing market conditions have negatively impacted transaction volumes, with the existing home business experiencing a transaction value decline of 4.2% to 21.5 trillion yuan, and new home business transaction value down by 8.2% to 890.9 billion yuan [6]. - The home decoration business reported a net income of 15.4 billion yuan, growing by 4.4%, while the rental service segment saw a significant increase in net income to 21.9 billion yuan, up by 52.8% [6].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [4]. Core Insights - The company, "Ming Ming Hen Mang," is a leading player in the bulk retail sector, leveraging an efficient business model to create a strong operational moat. The company is experiencing rapid store expansion and improving operational efficiency, leading to sustained revenue growth. Revenue projections for 2025-2027 are estimated at 614.2 billion, 801.3 billion, and 936.4 billion CNY, with year-on-year growth rates of 56.1%, 30.5%, and 16.9% respectively. Net profit is expected to reach 23.8 billion, 35.4 billion, and 44.3 billion CNY, with corresponding growth rates of 185.5%, 48.7%, and 25.3% [4][81]. Company Overview - Ming Ming Hen Mang is the largest chain retailer of snacks and beverages in China, operating under two main brands: "Snacks Very Busy" and "Zhao Yi Ming Snacks." The company was formed through the merger of these two brands in November 2023 and has rapidly expanded its store count to nearly 20,000 by September 2025 [16][21]. - The company has demonstrated strong financial performance, with revenue increasing from 4.29 billion CNY in 2022 to 46.37 billion CNY in the first three quarters of 2025, reflecting a robust growth trajectory [21][24]. Industry Analysis - The domestic retail market for snacks and beverages is projected to exceed 3.7 trillion CNY by 2024, with significant growth potential in lower-tier markets. The lower-tier market is expected to grow faster than higher-tier markets, indicating substantial opportunities for expansion [5][39]. - The retail industry is characterized by a fragmented competitive landscape, with Ming Ming Hen Mang positioned as a leading player in the bulk retail segment. The company is expected to capture a growing share of the market as the proportion of sales through bulk retail channels continues to rise [42][52]. Operational Efficiency - The company employs a highly efficient supply chain model, selecting quality manufacturers and utilizing large-scale procurement to enhance turnover efficiency. The rapid expansion of stores is supported by a modern franchise system, allowing for swift growth and improved operational metrics [6][59]. - The company has a strong digital infrastructure that supports its operations, including a self-developed system for product selection, ordering, and inventory management, which enhances efficiency across its extensive store network [74].

Investment Rating - The report assigns a "Buy" rating for King’s Ray Biotechnology (1548.HK) based on its strong performance and growth potential in the biopharmaceutical market [1]. Core Insights - King’s Ray Biotechnology reported robust growth in 2025, with total revenue reaching $960 million, a year-on-year increase of 61.4%. The adjusted net profit was $230 million, reflecting a significant growth of 285% [2][6]. - The company operates three main business segments: Life Sciences, Prosperity Bio, and BestJet, all showing positive operational trends [2]. Business Segment Summaries Life Sciences - In 2025, the Life Sciences segment generated $522 million in revenue, a 14.8% increase year-on-year, with an adjusted gross profit of $267 million, up 12.5% [3]. - The European market showed significant growth, with revenue share increasing from 16% in 2024 to 19% in 2025 [3]. - The segment aims for a revenue growth of 15-18% in 2026, targeting an adjusted gross margin of approximately 52% [5]. Prosperity Bio - Prosperity Bio achieved $389 million in revenue in 2025, a remarkable 309.1% increase. Excluding milestone revenues, the organic growth was 21% [4]. - The segment added 41 new CDMO projects, a 46% increase, and aims for a revenue growth of 20-25% in 2026 [5]. - The segment is expected to maintain high growth rates as more projects enter late-stage clinical trials [4]. BestJet - BestJet reported $58 million in revenue for 2025, a 7.9% increase, with an adjusted gross profit of $23 million [5]. - The segment is focusing on innovative product development, with AI enhancing research efficiency by 140% [5]. - The revenue from innovative products increased from 40% in 2024 to 44% in 2025, indicating strong potential for future growth [5]. Financial Projections - The company forecasts revenues of $807 million, $948 million, and $1.116 billion for 2026, 2027, and 2028, respectively, with corresponding net profits of $91 million, $183 million, and $239 million [7]. - The projected P/E ratios for these years are 34.35, 17.13, and 13.14, indicating a favorable valuation outlook [7].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved a total revenue of 94.58 billion yuan in 2025, reflecting a year-on-year growth of 1.2%. However, the net profit attributable to shareholders decreased by 26.3% to 2.99 billion yuan, and the non-GAAP net profit fell by 30.4% to 5.02 billion yuan [7][8] - The decline in profit is attributed to an increase in low-margin business revenue and a decrease in profit margins from existing home transactions, leading to an overall gross margin drop of 3.2 percentage points to 21.4% [7] - The company has been actively returning capital to shareholders, with a total buyback amounting to 920 million USD, a 29% increase year-on-year, and cash dividends of approximately 300 million USD, totaling around 1.22 billion USD in shareholder returns, which is 170% of the non-GAAP net profit [7] - The company expanded its active store count to 58,000, a 17.5% increase year-on-year, while the number of active agents remained stable at 445,600 [7] - The existing home business generated a Gross Transaction Value (GTV) of 21,515 billion yuan, down 4.2% year-on-year, with revenue declining by 11.3% [7] - The new home business showed resilience with a GTV of 8,909 billion yuan, down 8.2%, but better than the industry average decline of 13.0% [7] - The rental business saw significant growth, with revenue increasing by 52.8% to 21.9 billion yuan, benefiting from an increase in managed properties [7] - The report forecasts non-GAAP net profits of 6.58 billion yuan, 7.50 billion yuan, and 8.50 billion yuan for 2026, 2027, and 2028 respectively, with corresponding non-GAAP P/E ratios of 21.1X, 18.5X, and 16.3X [7] Financial Summary - Total revenue for 2024 is projected at 93.46 billion yuan, with a year-on-year growth of 20.16% [1] - The company’s earnings per share (EPS) for 2025 is estimated at 0.85 yuan, with a P/E ratio of 46.32 [1] - The company’s total assets are expected to reach 116.67 billion yuan by 2025, with a debt-to-asset ratio of 43.05% [6][8]

Investment Rating - The report assigns a "Sell" rating to MTR Corporation with a target price of HKD 24 [1] Core Insights - MTR Corporation reported a basic net profit of HKD 16.7 billion for the year ending December, a 4% year-on-year decline, which met UBS's expectations. However, recurring EBIT fell by 13%, which was below UBS's forecast [1] - MTR is currently in the planning stages for the South Island Line (West) and the Pak Shek Kok Station, along with the second phase of the Northern Link. UBS anticipates that the capital expenditures for these three new projects will be disclosed in the second half of this year, expecting a negative market reaction to the lower-than-expected recurring profits [1] - In terms of land bidding, MTR plans to launch tenders for the second phase of the Kam Sheung Road Station and the second phase of the Tuen Mun District 16 Station within the next 12 months. Despite a recent market recovery, UBS believes that the land price for Tuen Mun, which has a large development scale of 5,510 units, has limited upside compared to the first phase price of HKD 4,314 per square foot, including one-time payments and profit sharing. Nevertheless, the final land price is expected to remain below the HKD 5,621 per square foot compensation amount [1] - MTR has guided a maintenance capital expenditure of HKD 41.6 billion for the next three years, which is expected to remain relatively stable on a half-yearly comparison [1]

Investment Rating - The report assigns a "Neutral" rating to Swire Properties (00019) with a target price of HKD 72.7 [1] Core Insights - Swire Properties reported a 5% year-on-year increase in recurring core profit to HKD 9.8 billion, which was 4% lower than the bank's forecast, primarily due to weaker-than-expected contributions from the beverage business [1] - The company announced a 13% year-on-year increase in annual dividend per share to HKD 3.8, which was unexpected and indicates a payout ratio of 53% of recurring core profit, projected to be 51% in 2024 [1] - Management reiterated a progressive dividend policy based on the recovery of the aviation business over the past five years, expecting the payout ratio to remain above 50% of recurring core profit, with annual single-digit growth in dividend per share [1] - The net debt ratio is expected to improve from 22.1% in December 2024 to 20.6% at the end of last year [1] - The report anticipates an 8% year-on-year growth in underlying EBITDA, benefiting from the inclusion of beverage business performance from Thailand and Laos starting October 2024 [1] - Dividend income from joint ventures and associates is expected to increase by 3%, mainly reflecting the dividend distribution from Cathay Pacific [1] - The report projects continued improvement in cash flow for Swire Properties this year [1]

Investment Rating - The report assigns a "Buy" rating for King’s Ray Biotechnology (1548.HK) based on its strong performance and growth potential in the biopharmaceutical market [1]. Core Insights - King’s Ray Biotechnology reported a robust revenue of $960 million for 2025, marking a year-on-year growth of 61.4%. The adjusted net profit reached $230 million, reflecting a significant increase of 285% [1][2]. - The company operates three main business segments: Life Sciences, Prosperous Biotech, and BestJet, all showing positive growth trends [2]. Summary by Business Segment Life Sciences - In 2025, the Life Sciences segment generated $522 million in revenue, a 14.8% increase year-on-year. The adjusted gross profit was $267 million, with a gross margin of 51% [3]. - The European market showed significant growth, with revenue share increasing from 16% in 2024 to 19% in 2025. The segment is expected to maintain its leading position in the industry [3]. Prosperous Biotech - Prosperous Biotech achieved $389 million in revenue, a remarkable growth of 309.1%. Excluding milestone revenues, the organic growth was 21% [4]. - The segment added 41 new CDMO projects, a 46% increase, and completed multiple GMP batches for multinational pharmaceutical companies [4]. BestJet - BestJet reported $58 million in revenue, a 7.9% increase year-on-year, with an adjusted gross profit of $23 million [5]. - The segment is focusing on strategic R&D investments, with a 140% increase in R&D efficiency due to AI integration [5]. 2026 Performance Guidance - The company provided strong performance guidance for 2026, with expected revenue growth of 15-18% for the Life Sciences segment and 20-25% for Prosperous Biotech [5]. - BestJet aims for a revenue increase of 10-15% in 2026, indicating a comprehensive acceleration in growth confidence compared to 2025 [5].